Choukroun G, Hajjar R, Kyriakis J M, Bonventre J V, Rosenzweig A, Force T
Renal Unit, and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA.
J Clin Invest. 1998 Oct 1;102(7):1311-20. doi: 10.1172/JCI3512.
The signal transduction pathways governing the hypertrophic response of cardiomyocytes are not well defined. Constitutive activation of the stress-activated protein kinase (SAPK) family of mitogen-activated protein (MAP) kinases or another stress-response MAP kinase, p38, by overexpression of activated mutants of various components of the pathways is sufficient to induce a hypertrophic response in cardiomyocytes, but it is not clear what role these pathways play in the response to physiologically relevant hypertrophic stimuli. To determine the role of the SAPKs in the hypertrophic response, we used adenovirus-mediated gene transfer of SAPK/ERK kinase-1 (KR) [SEK-1(KR)], a dominant inhibitory mutant of SEK-1, the immediate upstream activator of the SAPKs, to block signal transmission down the SAPK pathway in response to the potent hypertrophic agent, endothelin-1 (ET-1). SEK-1(KR) completely inhibited ET-1-induced SAPK activation without affecting activation of the other MAP kinases implicated in the hypertrophic response, p38 and extracellular signal-regulated protein kinases (ERK)-1/ERK-2. Expression of SEK-1(KR) markedly inhibited the ET-1-induced increase in protein synthesis. In contrast, the MAPK/ERK kinase inhibitor, PD98059, which blocks ERK activation, and the p38 inhibitor, SB203580, had no effect on ET-1-induced protein synthesis. ET-1 also induced a significant increase in atrial natriuretic factor mRNA expression as well as in the percentage of cells with highly organized sarcomeres, responses which were also blocked by expression of SEK-1(KR). In summary, inhibiting activation of the SAPK pathway abrogated the hypertrophic response to ET-1. These data are the first demonstration that the SAPKs are necessary for the development of agonist-induced cardiomyocyte hypertrophy, and suggest that in response to ET-1, they transduce critical signals governing the hypertrophic response.
调控心肌细胞肥大反应的信号转导通路尚未完全明确。通过过表达该通路各种组分的激活突变体,使丝裂原活化蛋白(MAP)激酶的应激激活蛋白激酶(SAPK)家族或另一种应激反应MAP激酶p38组成性激活,足以在心肌细胞中诱导肥大反应,但尚不清楚这些通路在对生理相关肥大刺激的反应中起何种作用。为了确定SAPK在肥大反应中的作用,我们使用腺病毒介导的基因转移技术,导入SAPK/ERK激酶-1(KR)[SEK-1(KR)],它是SEK-1的显性抑制突变体,而SEK-1是SAPK的直接上游激活剂,以此来阻断在强效肥大剂内皮素-1(ET-1)作用下SAPK通路的信号传递。SEK-1(KR)完全抑制了ET-1诱导的SAPK激活,而不影响参与肥大反应的其他MAP激酶即p38和细胞外信号调节蛋白激酶(ERK)-1/ERK-2的激活。SEK-1(KR)的表达显著抑制了ET-1诱导的蛋白质合成增加。相比之下,阻断ERK激活的MAPK/ERK激酶抑制剂PD98059和p38抑制剂SB203580对ET-1诱导的蛋白质合成没有影响。ET-1还诱导心房利钠因子mRNA表达显著增加,以及具有高度有序肌节的细胞百分比增加,这些反应也被SEK-1(KR)的表达所阻断。总之,抑制SAPK通路的激活消除了对ET-1的肥大反应。这些数据首次证明,SAPK对于激动剂诱导的心肌细胞肥大的发展是必需的,并表明在对ET-1的反应中,它们转导了调控肥大反应的关键信号。